PMID- 28352705
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240324
IS  - 2391-5463 (Print)
IS  - 2391-5463 (Electronic)
VI  - 10
IP  - 1
DP  - 2015
TI  - Effect of puerarin on human choriocarcinoma cells.
PG  - 267-277
LID - 10.1515/med-2015-0039 [doi]
AB  - OBJECTIVE: To discuss the effect of puerarin on human choriocarcinoma cells. 
      METHODS: Survival rates under puerarin monotherapy, fluorouracil (5-FU) 
      monotherapy and puerarin in combination with 5-FU were detected by MTT assay. 
      Apoptotic morphology was observed with Hoechst 33258 staining. Apoptosis rates 
      were detected with flow cytometry. Expressions of AKT, mechanistic target of 
      rapamycin (mTOR), and P70S6K mRNAs and phosphorylated proteins were detected by 
      RT-PCR and Western blot. Tumor-bearing mice were administered puerarin and 
      puerarin+5-FU, and serum levels of beta-human chorionic gonadotropin (beta-HCG) were 
      measured. RESULTS: Proliferation inhibition and apoptosis rates of JEG-3 cells 
      were positively correlated with puerarin concentration, which increased in the 
      puerarin+5-FU group. Expression levels of AKT, mTOR, P70S6K mRNAs, and 
      phosphorylated proteins decreased significantly after action of puerarin at 
      different concentrations. With increasing puerarin concentration, expression of 
      cleaved-caspase-3 in JEG-3 cells increased, whereas that of Bcl-2 decreased. 
      Puerarin significantly inhibited tumor growth in choriocarcinoma-bearing SCID 
      mice. Serum beta-HCG levels were significantly lower than those of control group 
      after administration. Magnitude of beta-HCG decline was positively correlated with 
      concentration.. CONCLUSION: Puerarin+5-FU inhibited proliferation of JEG-3 
      choriocarcinoma cells and promoted their apoptosis, being associated with the 
      mTOR signaling pathway.
FAU - Lidao, Bao
AU  - Lidao B
AD  - Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, 
      Hohhot 010059, PR China.
FAU - Yi, Wang
AU  - Yi W
AD  - Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, 
      Hohhot 010059, PR China.
FAU - Ruilian, Ma
AU  - Ruilian M
AD  - Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, 
      Hohhot 010059, PR China.
FAU - Xianhua, Ren
AU  - Xianhua R
AD  - Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, 
      Hohhot 010059, PR China.
FAU - Haijun, Lv
AU  - Haijun L
AD  - Department of Scientific Research, Affiliated Hospital of Inner Mongolia Medical 
      University, Hohhot 010059, PR China.
FAU - Agula, B
AU  - Agula B
AD  - College of Mongolian Medicine, Inner Mongolia Medical University, Hohhot 010059, 
      PR China.
LA  - eng
PT  - Journal Article
DEP - 20150428
PL  - Poland
TA  - Open Med (Wars)
JT  - Open medicine (Warsaw, Poland)
JID - 101672167
PMC - PMC5152980
OTO - NOTNLM
OT  - JEG-3
OT  - choriocarcinoma
OT  - fluorouracil
OT  - puerarin
EDAT- 2015/04/28 00:00
MHDA- 2015/04/28 00:01
PMCR- 2015/04/28
CRDT- 2017/03/30 06:00
PHST- 2015/01/31 00:00 [received]
PHST- 2015/03/19 00:00 [accepted]
PHST- 2017/03/30 06:00 [entrez]
PHST- 2015/04/28 00:00 [pubmed]
PHST- 2015/04/28 00:01 [medline]
PHST- 2015/04/28 00:00 [pmc-release]
AID - med-2015-0039 [pii]
AID - 10.1515/med-2015-0039 [doi]
PST - epublish
SO  - Open Med (Wars). 2015 Apr 28;10(1):267-277. doi: 10.1515/med-2015-0039. 
      eCollection 2015.